Zevra Therapeutics, a commercial-stage company focused on therapies for rare diseases, announced on March 16, 2026, that it has agreed to sell its serdexmethylphenidate (SDX) portfolio, including AZSTARYS and KP1077, to Commave Therapeutics SA for $50 million, according to GlobeNewswire PE. As part of this agreement, the companies settled a lawsuit that Commave had initiated in Delaware Chancery Court in 2024, following a 2019 license agreement where Zevra granted Commave an exclusive license to certain SDX products.
Details of the Transaction
Zevra’s President and Chief Executive Officer, Neil F. McFarlane, stated that the company is pleased with the mutually beneficial agreement and believes the SDX programs are in capable hands with Commave. Prior to finalizing the sale, Zevra repaid the principal balance on its $63 million term loan, resulting in a debt-free balance sheet. This transaction allows Zevra to focus on its mission of advancing therapies for rare diseases, as the company is commercializing products for conditions like Niemann-Pick disease type C.
Background on the Partnership
Zevra and Commave had a productive partnership stemming from the 2019 license agreement, which involved SDX products. The 2024 litigation in Delaware marked a dispute between the parties, and the sale agreement resolves this matter. Zevra, listed on NasdaqGS as ZVRA, emphasizes its commitment to rare disease therapies through this strategic move.
Zevra’s Strategic Focus
Following the sale, Zevra aims to progress its pipeline and expand access to treatments, building on its foundation as a company that has brought therapies from development to market. As widely known in the biotechnology sector, such transactions can provide companies with enhanced financial flexibility, which in this case includes Zevra’s strengthened balance sheet after repaying its loan, according to GlobeNewswire PE.
